Polyene Antibiotics
The polyene antifungal antibiotics, and in particular nystatin, are probably the most widely used compounds in the treatment of candidal vaginitis, although a wide range of other effective compounds exists. The polyenes are macrolide antibiotics produced mainly by streptomyces species. They act on sensitive organisms by binding to sterol sites which are present on the cytoplasmic membrane of fungal cells, thus interfering with its permeability. Those used for the treatment of candidal infections of the vagina are shown in Table 1 .
Nystatin is very effective for local treatment, but is not absorbed when taken by mouth and cannot be given parenterally. Amphotericin B is more active in vitro than nystatin and can be used topically. However, unlike nystatin, amphotericin B can also be given by the intravenous route and is effective not only against yeasts but also against certain filamentous fungi causing deep mycoses. Natamycin, used topically for the treatment of candidal infections, is the only one of these listed polyene antibiotics to be active against Trichomonas vaginalis. The remaining polyene antibiotic, candicidin, is used mainly for the topical treatment of vaginal infections.
Neither primary resistance nor the development of resistant strains of fungi during therapy have presented problems during the often prolonged use of the polyene antibiotics. A recent leading article on vaginal candidosis in the British Medical Journal (1976) stated that amphotericin B was exceptional among the antifungal agents used for the treatment of such conditions, in that resistance to it may develop.
This statement was challenged in subsequent correspondence. In particular, Hurley & Wright (1976) remarked that there is no evidence that Candida albicans is ever found naturally to be resistant to amphotericin B, despite the many thousands of isolates tested. They also pointed out that an Editorial statement that C. albicans shows a decline in sensitivity to amphotericin B when exposed to the drug is of little clinical importance, since loss of virulence is reported in such strains. In addition, induced resistance is reversible on withdrawal of the polyene to which the strain has been exposed. This would rule out any selective breeding of strains.
Although there are patients who fail to respond to therapy, other factors such as reinfection and Dr Yvonne M Clayton inadequate length of treatment are more likely to be responsible than the occurrence of resistance to the drug. Until more evidence has been advanced on the development of resistance during treatment, there would appear to be no reason to withhold topical use of amphotericin B if this is indicated.
The polyenes are available as vaginal pessaries (in an inert or effervescent base) and as creams or ointments. It has been suggested (Morese 1975) that better results are obtained by using ointments or creams inserted into the vagina with an applicator. Large numbers of comparative studies would be required to establish this conclusively. Patient acceptability is probably the deciding factor when a choice between forms of treatment has to be made.
Since the gastrointestinal tract may be a reservoir for reinfection by C. albicans, it is frequently of value to give oral therapy at the same time as the vaginitis is being treated topically. Oral nystatin and amphotericin B tablets which are not absorbed when taken by mouth are very effective for removing yeasts from the gut.
Imidazoles
In recent years the realization of the antifungal properties of imidazole derivatives has produced two compounds, clotrimazole and miconazole (Table 1) , which are not only effective against candida and other yeasts, but also against dermatophytes and many other fungal species pathogenic to man. They also have some antibacterial activity. In addition, clotrimazole shows in vitro trichomonicidal activity and is possibly somewhat effective in vivo. 
Clotrimazole is a tritylimidazole derivative which acts on the cell membrane. Iwata and his colleagues (1973) suggested that fungicidal concentrations of clotrimazole damaged the permeable membrane and that leakage of intracellular phosphorus compounds and potassium ions resulted, with the consequent inhibition of macromolecular synthesis. The drug is very active in vivo against candida, the majority of strains being inhibited by 2 mg/l or less, and killed by less than 10 mg/l of the drug (Holt 1974a).
Miconazole nitrate is a phenethyl imidazole derivative with a range of antifungal activity similar to that of clotrimazole, but it is more inhibitory against Gram-positive cocci than is clotrimazole (Holt 1972) . The action of miconazole appears to depend on binding to fungal cell membranes and selective inhibition of purine and glutamine uptake (Van den Bossche 1974). There have been no reports of primary resistance to these imidazoles, nor of the emergence of resistant strains of candida or other fungi during treatment.
Both these compounds are available as creams for the topical treatment of fungal infections. Miconazole can also be given orally and by intravenous administration for the treatment of systemic mycoses. For use in vaginal infections, clotrimazole is presented in tablet form and miconazole is available as pessaries or cream. The preparations are well tolerated by the majority of patients. Transient local irritation has occasionally been reported.
Other Compounds
Other compounds used in the treatment of candidal vaginitis are also shown in Table 1 . Apart from chlordantoin, the compounds listed are also active against trichomonal and some bacterial infections. Nifuratel is available in oral form for trichomonal infections and as pessaries for candidal infections. The other drugs are for vaginal application only in the form of pessaries, creams or gels. Hydrargaphen and povidoneiodine have the broadest spectra of activity.
The antifungal compounds in current use for the topical treatment of candidal vaginitis are effective in the majority of cases, particularly in producing significant improvement in symptoms and signs of vaginitis and vulvitis. There have been many clinical studies to try to determine whether one compound is more effective than another. Variations in numbers of patients, lengths of treatment and different methods of assessing results all make comparisons among such studies difficult. However, a few examples of clinical trials are quoted to show that the more recently introduced imidazole compounds appear to be as efficient as the polyene antibiotics and other drugs.
Thus, Masterton et al. (1975) in a study of 141 patients with candidal vaginitis confirmed by positive cultures of C. albicans, compared six-day clotrimazole therapy with six days of nystatin therapy. They found that, as judged by negative culture results, clotrimazole produced a 93 % cure rate compared with 74% for the group treated with nystatin when patients were reviewed three weeks after treatment had stopped. This trial was carried out to assess the efficacy of clotrimazole after a six-day course of treatment and it was realized that this period is less than half the recommended course of nystatin therapy.
In a similarly conducted trial, with cure defined as complete relief of symptoms and negative mycological findings at least thirty days after completion of therapy, Davis et al. (1974) compared fourteen days of treatment with miconazole with nystatin; they found that 91 % of patients treated with miconazole were cured compared with 77 % of those treated with nystatin. In these two trials, the differences were statistically significant.
In a comparative trial of miconazole, amphotericin and povidone-iodine, Warren et al. (1974) found that miconazole gave the highest cure rate (90 %) as assessed by negative microscopy and culture results. Amphotericin (75%) and povidone-iodine (65 %) were not as effective. However, vaginitis and vulvitis were improved by all the compounds. The length of treatment in this trial was ten days and patients were assessed four days after the end of therapy. Morris & Sugrue (1975) in a double-blind trial comparing miconzaole with chlordantoin found that after ten days of therapy there was no statistically significant difference between the cure rates as assessed by patients becoming culture negative for C. albicans. After a second course of ten days of treatment in those patients with candidal vaginitis, the overall cure rate with miconzaole was significantly greater than that with chlordantoin. It can be seen from these few examples that the length of treatment given varied considerably. The recommended times for treatment are shown in Table 2 , and range from six days for clotrimazole to thirty days for hydrargaphen. Masterton et al. (1976) have pointed out that in their experience, the shorter the course of treatment the more likely the patients are to complete it. However, Oates & Davidson (1974) found in their open study of patients with candidal vaginitis that they could improve the cure rate from 88 % in those patients using a six-day course of clotrimazole to 96% in those women who were treated for fourteen days.
Relapse or reinfection still remains a problem. The follow-up period in many studies is too short to determine whether one antifungal compound is superior to another in completely eradicating the causative fungus. It has been suggested that an effective and nontoxic systemic agent is required before completely satisfactory therapeutic results can be achieved.
In this context, one very potent anticandidal agent which has not been mentioned is 5-fluorocytosine. This pyrimidine derivative is well absorbed and distributed following oral administration and has low toxicity. However, a disadvantage in the use of 5-fluorocytosine is the occurrence of resistance both in vitro and in vivo. Primary resistance present in strains which ha-ve never been exposed to the drug has been reported in as many as 12 % of C. albicans strains isolated from clinical material (Hamilton-Miller 1972) and the emergence of resistant strains during treatment has been a cause of therapeutic failure. For these reasons, the topical use of 5-fluorocytos,ne has been discouraged (Holt 1974b) .
There exists a range of antifungal drugs available for the treatment of candidal vaginitis. They may be compared by differences in their in vivo activity and even more by their effectiveness as assessed by clinical studies. Patient acceptance of such factors as the length of treatment and the form in which the compound is introduced may, however, ultimately decide which drug is nost successful.
DISCUSSION
Dr L Cohen (Cardiff) asked the speakers for comments on a recent paper by R N Grunenberg and A Leakey (1976, British Medical Journal iv, 908) on the treatment of 3 cases of urinary infection with Candida albicans, using nifuratel. Professor J R Hobbs (London) said that amphotericin B was used among patients with agranulocytosis to keep them free from systemic candidiasis, but it produced extensive liver damage and if other drugs were available he would not favour its use. He also believed that it could be absorbed.
Liver disease was not related to dose as was previously thought. It was unpredictable and some patients might suddenly become jaundiced unexpectedly and at low dosages, whereas others tolerated high doses. He felt that we were not sure of its systemic effects and in the presence of any other effective agent he would discourage its use. Dr Clayton reiterated her belief that there was no justification for withholding it from topical application because of the risk of resistance. Other drugs may be used in preference, but if amphotericin was the only one effective she saw no reason against using it topically.
Dr R S Morton (Sheffield) had been told that miconazole could sometimes be absorbed by clothing, particularly underwear. If it remained in these garments and if residual faces on the underwear was a source of vaginal candida, then miconazole might have an effect in minimizing the number of recurrences by autoinfection. Dr J D Oriel (London) said that the reason why pessary treatments had never worked for trichomoniasis was that it did not attack the organisms in the urethra. This poi-nt was widely known and he made it only to suggest that the efficacy or .otherwise of various pessaries against Trichomonas vaginalis should be disregarded when their clinical use against candida was being considered. Dr R Y Cartwright (Guildford) asked Dr Clayton whether the fact that polyenes had little or no antibacterial activity, whereas imidazoles had, was likely to enhance their effectiveness in the treatment of vaginal candidosis. Dr Clayton did not believe that antibacterial activity would have any significance in the treatment of vaginal candidosis. She thought it more relevant in the treatment of topical candidal infections of the intertriginous zones.
